India has launched the first indigenous antibiotic for drug-resistant infections. Known as 'Nafithromycin,' the drug has been ...

Discover Nafithromycin Indias first indigenous antibiotic revolutionising the fight against drug-resistant pneumonia with unmatched efficacy and global recognition English हिन्दी ...

India has developed a new antibiotic, nafithromycin (Miqnaf), to combat drug-resistant pneumonia. Developed by Wockhardt with BIRAC support, this first-of-its-kind Indian antibiotic is more potent ...

As the world grapples against the evolving threat of antimicrobial resistance (AMR), India has made a significant stride in developing a new antibiotic, Nafithromycin. It took 30 years and Rs 500 ...

As the world tackles antimicrobial resistance (AMR), the development of antibiotic Nafithromycin marks a significant milestone, said the Government, hailing it as the country’s first indigenous ...

In a ground breaking step for India’s biotechnology sector, Union Minister Dr. Jitendra Singh has formally launched the first indigenous antibiotic ‘Nafithromycin’ for resistant infections ...

Animal reservoirs of mpox; an antibiotic breakthrough for pneumonia; understanding apathy in cancer patients; the health benefits of nature interventions; regenerating human teeth ...

Wockhardt's shares rose 14.20% after the company completed a pivotal phase 3 pneumonia study of its macrolide antibiotic, Nafithromycin WCK 4873. The three-day treatment with Nafithromycin was ...

Wockhardt Bio AG and Jemincare have partnered for Wockhardt’s novel patented antibiotic WCK 4873 (INN: Nafithromycin) in People’s Republic of China, Hong Kong, Macau and Taiwan for the ...

Wockhardt's Nafithromycin was evaluated in multicentre double-blind Phase 3 pneumonia study and its three-day course was as effective as seven-day therapy with Moxifloxcain. English.